Surgery, Anesthesia, Anticoagulant, Thrombosis and Pulmonary embolism are his primary areas of study. His work on Warfarin expands to the thematically related Surgery. His Anesthesia research is multidisciplinary, incorporating perspectives in Rivaroxaban, Idraparinux, Heparin, Placebo and Complication.
The Anticoagulant study combines topics in areas such as Antithrombotic, Vitamin K antagonist, Randomization, Prospective cohort study and Tinzaparin sodium. His Thrombosis research includes elements of Radiology and Vein. His research investigates the connection between Pulmonary embolism and topics such as Chemotherapy that intersect with problems in Semuloparin, Multicenter trial and Cancer.
Alexander G.G. Turpie spends much of his time researching Internal medicine, Surgery, Thrombosis, Anesthesia and Pulmonary embolism. His Internal medicine research focuses on Cardiology and how it relates to Aspirin. His research on Surgery frequently connects to adjacent areas such as Warfarin.
His studies in Thrombosis integrate themes in fields like Clinical trial, Radiology, Incidence and Vein. Alexander G.G. Turpie has included themes like Fondaparinux, Low molecular weight heparin, Heparin, Anticoagulant and Placebo in his Anesthesia study. As a member of one scientific family, Alexander G.G. Turpie mostly works in the field of Low molecular weight heparin, focusing on Antithrombotic and, on occasion, Fibrinolytic agent.
His primary areas of investigation include Internal medicine, Rivaroxaban, Atrial fibrillation, Stroke and Thrombosis. His work in Internal medicine tackles topics such as Cardiology which are related to areas like Lower risk. His studies deal with areas such as Surgery, Discontinuation, Venous thromboembolism and Clinical trial as well as Rivaroxaban.
As part of the same scientific family, Alexander G.G. Turpie usually focuses on Surgery, concentrating on Antithrombotic and intersecting with Fibrinolytic agent. His biological study spans a wide range of topics, including Arthroplasty and Intensive care medicine. His study in Deep vein is interdisciplinary in nature, drawing from both Pulmonary embolism and Heparin.
Alexander G.G. Turpie mainly focuses on Internal medicine, Stroke, Atrial fibrillation, Rivaroxaban and Thrombosis. His work deals with themes such as Diabetes mellitus, Prospective cohort study, Cohort and Comorbidity, which intersect with Stroke. Gastrointestinal bleeding and Myocardial infarction is closely connected to Discontinuation in his research, which is encompassed under the umbrella topic of Rivaroxaban.
Thrombosis is a subfield of Surgery that Alexander G.G. Turpie studies. Alexander G.G. Turpie works in the field of Surgery, focusing on Randomized controlled trial in particular. His Deep vein research incorporates elements of Heparin, Anesthesia and Fondaparinux.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
R Altman;L Carreras;R Diaz;E Figueroa.
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
R Collins;R Peto;M Flather;S Parish.
The Lancet (1995)
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
Philip S. Wells;David R. Anderson;Marc Rodger;Jeffrey S. Ginsberg.
Thrombosis and Haemostasis (2000)
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
M. Cohen;C. Demers;E. P. Gurfinkel;A. G. G. Turpie.
The New England Journal of Medicine (1997)
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
Meyer Michel Samama;Alexander Thomas Cohen;Jean-Yves Darmon;Louis Desjardins.
The New England Journal of Medicine (1999)
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Michael R. Lassen;Walter Ageno;Lars C. Borris;Jay R. Lieberman.
The New England Journal of Medicine (2008)
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Mark Levine;Michael Gent;Jack Hirsh;Jacques Leclerc.
The New England Journal of Medicine (1996)
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
E. M. Antman;C. H. Mccabe;E. P. Gurfinkel;A. G. G. Turpie.
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Clive Kearon;Michael Gent;Michael Gent;Jack Hirsh;Jack Hirsh;Jeffrey Weitz.
The New England Journal of Medicine (1999)
ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION
D Hunt;J Varigos;F Dienstl;P Lechleitner.
The Lancet (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: